je.st
news
Regeneron Pharms Downgraded by Brean Murray
2013-01-18 05:36:43| Biotech - Topix.net
A number of other firms have also recently commented on REGN. Analysts at Robert W. Baird raised their price target on shares of Regeneron Pharms from $176.00 to $205.00 in a research note to investors on Tuesday.
Tags: murray
downgraded
brean
regeneron
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||